ArriVent BioPharma Advances Cancer Therapeutics Pipeline

TipRanksNov 19 12:03

H.C. Wainwright Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $36

Futu NewsNov 15 19:34 · Ratings

LifeSci Capital Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $38

Futu NewsNov 15 19:34 · Ratings

HC Wainwright & Co. Reiterates Buy on ArriVent BioPharma, Maintains $36 Price Target

BenzingaNov 15 19:26 · Ratings

ArriVent BioPharma, Inc.: Promising Clinical Trials and Strategic Collaborations Drive Buy Rating

TipRanksNov 15 19:05 · Ratings

ArriVent BioPharma GAAP EPS of -$0.61 Beats by $0.11

Seeking AlphaNov 15 16:30